Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYu YaoRJRan Ji

Discussion

Loading...

Member takes

Overview

Secondary analysis finds overall response rates in chronic graft-versus-host disease with giliary kinetics and organ-specific outcomes.

Key Points

  • To characterize time to response and organ-specific responses to belumosudil in chronic graft-versus-host disease (cGVHD).
  • Secondary analysis of Phase 2 ROCKstar trial data
  • Clinical response evaluated using NIH consensus criteria
  • Participants included those identified as responders to belumosudil
  • 75% of participants were identified as responders
  • Cumulative overall response rates at >12 months reached 100%
  • Response kinetics varied by organ, with the most rapid responses seen in gastrointestinal tract and joint

Cite This Study

Yao et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db99https://doi.org/10.1182/blood-2025-6004
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.2025
  2. 2Real-world outcomes in refractory chronic graft-<i>versus</i>-host disease: the Italian multicenter experience with belumosudil2026
  3. 3Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety2025
  4. 4Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft‐Versus‐Host Disease: A Systematic Review and Meta‐Analysis2026
  5. 5Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study2026